Envista (NYSE:NVST) Given New $19.00 Price Target at Morgan Stanley

Envista (NYSE:NVST) had its price target dropped by stock analysts at Morgan Stanley from $20.00 to $19.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target points to a potential upside of 3.97% from the company’s previous close.

NVST has been the topic of a number of other research reports. Mizuho initiated coverage on Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a report on Thursday. Piper Sandler boosted their target price on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Wells Fargo & Company raised their price target on shares of Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Finally, Jefferies Financial Group boosted their price objective on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Envista currently has a consensus rating of “Hold” and a consensus target price of $20.13.

Envista Price Performance

NYSE:NVST opened at $18.28 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The company has a 50 day moving average price of $20.27 and a 200-day moving average price of $19.69. Envista has a 1-year low of $15.15 and a 1-year high of $23.00. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -2.82, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts forecast that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Polar Asset Management Partners Inc. raised its stake in Envista by 27.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 1,914,799 shares of the company’s stock worth $36,936,000 after purchasing an additional 417,549 shares during the period. Brickwood Asset Management LLP purchased a new stake in shares of Envista during the 4th quarter valued at approximately $40,037,000. Vise Technologies Inc. grew its position in Envista by 14.7% in the fourth quarter. Vise Technologies Inc. now owns 16,016 shares of the company’s stock worth $309,000 after acquiring an additional 2,056 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Envista by 15.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 492,736 shares of the company’s stock worth $9,505,000 after acquiring an additional 67,234 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in Envista by 66.6% during the fourth quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock worth $922,000 after acquiring an additional 19,100 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.